Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacteroides is a genus of Gram-negative, obligate anaerobic, non-spore-forming bacilli that represent a significant portion of the human gastrointestinal microbiota. While they are primarily commensal organisms that assist the host by breaking down complex polysaccharides and contributing to metabolic homeostasis, they are also highly significant opportunistic pathogens. They are the most common anaerobic bacteria isolated from clinical infections, such as intra-abdominal abscesses, peritonitis, and bacteremia, typically following a breach in the mucosal barrier. Treatment usually requires broad-spectrum anaerobic coverage, though the genus is noted for having among the highest rates of antibiotic resistance among anaerobes. Because 'Bacteroides' refers to an entire genus of bacteria rather than a specific protein, enzyme, or receptor, it is considered too broad to be classified as a single molecular target.
Antibiotics targeting this genus act through diverse mechanisms including DNA synthesis inhibition (nitroimidazoles), protein synthesis inhibition (lincosamides), and cell wall synthesis inhibition (beta-lactams/carbapenems).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacteroides.